• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

Video

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.

Transcript

How does vaccination influence response of patients with chronic lymphocytic leukemia to ibrutinib?

Ibrutinib is an immune-modulatory agent, so it has the potential to improve vaccine responses. However, we don't have enough data that's looking at this yet to have a firm conclusion as to how ibrutinib affects this. We have an ongoing studio that looks at vaccinating people and then treating them with ibrutinib or treating them with ibrutinib and treating them with vaccines that will answer the question as to whether or not ibrutinib can boost vaccine responses. We suspect, based on its immunologic actions, that it might, but that is something that we'll have to see.

Related Videos
Refat Rasul Srejon, MPH
1 expert is featured in this series.
Refat Rasul Srejon, MPH
Screenshot of an interview with Nicolas Girard, MD, PhD
4 experts in this video
4 experts in this video
Byoung Chul Cho, MD, PhD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.